The Swissmedic Marketing Authorisation for Global Health Products (MAGHP) Procedure

Progress update and lessons learned


Virtual Event on the MAGHP Procedure: A contribution to accelerating access to quality medical products in low and middle-income countries.

On Tuesday, 23 February 2021, Swissmedic, in collaboration with the Swiss Development and Cooperation Agency, held a virtual event on the Procedure for Marketing Authorisation for Global Health Products (MAGHP). The MAGHP Procedure is part of Swissmedic’s engagement in development cooperation, in accordance with its strategic objectives for 2019-2022. In line with these objectives, Swissmedic is committed to improving access to therapeutic products by strengthening regulatory systems in low- and middle-income countries. The event’s objective was to present the MAGHP Procedure and its benefits in terms of capacity-building and accelerated access to therapeutic products in the countries concerned. Swissmedic, representatives from the National Regulatory Authorities of Tanzania and Ghana as well as the WHO presented their experiences gained from participating in the procedure and shared their perspectives with regard to benefits and challenges. The concluding panel discussion helped to strengthen the common understanding of the procedure’s main benefits and served as a platform to exchange views on the current challenges. It was also an opportunity for discussing how to further improve the procedure.